Data Supplement from TLR7 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Non–Small Cell Lung Cancer

Supplemental Figures 1-10. Supplementary figure 1 shows that TLR7 antagonist IRS661 specifically blocks TLR7 expression by human A549 cells Supplementary figure 2 shows that TLR7 agonist induces chemoresistance in murine LL/2 cells Supplementary figure 3 shows the pro-tumoral effect of TLR7 stimulation with increasing doses of chemotherapy Supplementary figure 4 shows that Stimulation of TLR7 favors tumor growth and chemoresistance of murine LL/2 cells while TLR7 blockade with an antagonist inhibits tumor growth Supplementary figure 5 shows that TLR7 stimulation induces myeloid cell recruitment into LL/2 tumors in immunocompetent C57BL/6 mice Supplementary figure 6 shows Determining the optimal cutoff for the cohort of patients not treated with neo-adjuvant chemotherapy Supplementary figure 7 shows Determining the optimal cutoff for the cohort of patients treated with neo-adjuvant chemotherapy Supplementary figure 8 shows that non-responders patients to neo-adjuvant chemotherapy have a poor prognosis Supplementary figure 9 shows the correlation graph for TLR7 expression by tumor cells in metastatic lymph nodes and in primary lung tumor, after treatment with neo-adjuvant chemotherapy Supplementary figure 10 shows that High TLR7 expression on tumor cells is associated with low response to neo-adjuvant chemotherapy